Del Global Technologies and its Italian subsidiary, Villa Sistemi Medicali, announced that the government of Lithuania has awarded them an $8.25 million, two-year contract for a variety of x-ray systems.Del Global manufactures general and portable
Del Global Technologies and its Italian subsidiary, Villa Sistemi Medicali, announced that the government of Lithuania has awarded them an $8.25 million, two-year contract for a variety of x-ray systems.
Del Global manufactures general and portable x-ray systems, as well as dental and mammography units. It recently signed an agreement with the European Distribution Organization (SCAN, 8/2/00), granting the EDO the right to act as exclusive distributor of Del Globals medical imaging systems.
Countries in the EDO include Poland, the Czech Republic, the Slovak Republic, Hungary, Greece, Romania, Turkey, Bulgaria, Yugoslavia, Russia, and others, such as Lithuania, in the Commonwealth of Independent States.
Del Global also announced that the FDA has approved marketing of Villa Sistemis dental imaging system in the U.S.
Del Global obtained a 19% stake in Villa Sistemi in January, along with the nonrevocable option to increase its ownership share to 80%, and decided to exercise that option in April (SCAN 5/10/00). Del Global is based in Valhalla, NY, while Villa Sistemi is based in Milan.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.